Dr. Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary. He also serves as the Dean of MD Admissions and Director of the IBD Fellowship Program. He has been honoured with the Crohn’s Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease at the University of Calgary.
He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and has been recently recognized as a 2020 Clarivate Research Scholar for being cited in the top 1% of researchers cited in the world. He has co-authored 309 manuscripts, 7 book chapters, and 326 abstracts including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine.
He is a founding member of the Crohn’s Colitis Canada PACE initiative ( 5 million dollar grant) and National IBD Lead on the Canada Institutes of Health (CIHR) SPOR IMAGINE grant (25 million dollars) Dr. Panaccione is the principal investigator on several studies evaluating the efficacy and safety of new agents in subjects Crohn's disease and ulcerative colitis..His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care. He is a recognized authority on IBD therapeutics and has co-authored numerous guidelines for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut.